Back to News
Market Impact: 0.25
Zealand Publishes New Phase 2 Data For Petrelintide Showing Improved Cardiometabolic Benefits
Source: Nasdaq
Healthcare & Biotech
Zealand Pharma announced publication of new Phase 3 ZUPREME-1 trial results for petrelintide in weight management in The Lancet Diabetes & Endocrinology. Publication in a leading peer-reviewed journal is a positive validation milestone for the company’s obesity-treatment development program, although the article did not provide efficacy, safety, or financial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
ZEAL0.62
More News
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
- Walgreens owner nears $9 billion deal to sell Boots chain- WSJ
- Why is Toho stock volatile today?
- Lilly’s Foundayo shows cardiovascular safety in diabetes trial
- Nvidia is approaching a breakout level. Plus, what we want to see from Micron
- Moderna has been on a tear since mid-August. Citi now sees it plunging 60%